Fibrate: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In medicine, '''fibrates''' are antilipemic agents for treating hyperlipidemia. Fibrates lower triglycerides by being agonists of [[peroxisome proliferator-activated receptor a...) |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
{{TOC|right}} | |||
In [[medicine]], '''fibrates''' are [[antilipemic agent]]s for treating [[hyperlipidemia]]. Fibrates lower triglycerides by being agonists of [[peroxisome proliferator-activated receptor alpha]] (PPAR alpha)<ref name="pmid16567579">{{cite journal| author=Barter PJ, Rye KA| title=Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? | journal=Circulation | year= 2006 | volume= 113 | issue= 12 | pages= 1553-5 | pmid=16567579 | In [[medicine]], '''fibrates''' are [[antilipemic agent]]s for treating [[hyperlipidemia]]. Fibrates lower triglycerides by being agonists of [[peroxisome proliferator-activated receptor alpha]] (PPAR alpha)<ref name="pmid16567579">{{cite journal| author=Barter PJ, Rye KA| title=Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? | journal=Circulation | year= 2006 | volume= 113 | issue= 12 | pages= 1553-5 | pmid=16567579 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16567579 | doi=10.1161/CIRCULATIONAHA.105.620450 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> Examples include: | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16567579 | doi=10.1161/CIRCULATIONAHA.105.620450 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> Examples include: | ||
| Line 10: | Line 12: | ||
A [[systematic review]] of [[randomized controlled trial]]s of fibrates concluded "In addition to improving lipid profiles, fibrates are associated with an important decrease in nonfatal myocardial infarction, but do not substantially affect all-cause mortality."<ref name="pmid19698935">{{cite journal| author=Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P et al.| title=Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. | journal=Am J Med | year= 2009 | volume= 122 | issue= 10 | pages= 962.e1-8 | pmid=19698935 | A [[systematic review]] of [[randomized controlled trial]]s of fibrates concluded "In addition to improving lipid profiles, fibrates are associated with an important decrease in nonfatal myocardial infarction, but do not substantially affect all-cause mortality."<ref name="pmid19698935">{{cite journal| author=Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P et al.| title=Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. | journal=Am J Med | year= 2009 | volume= 122 | issue= 10 | pages= 962.e1-8 | pmid=19698935 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19698935 | doi=10.1016/j.amjmed.2009.03.030 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19698935 | doi=10.1016/j.amjmed.2009.03.030 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> | ||
==Research in synergy== | |||
There has been interest in the synergistic use of alpha and gamma PPAR agonists. Trials with dual agonists, the glitazars, were stopped for safety reasons. <ref>{{citation | |||
| journal =The British Journal of Diabetes and Vascular Disease | |||
| title = Goodbye Glitazars? | |||
| author = Deane Conlon | |||
| date = 3 October 2006 | |||
| url = http://www.medscape.com/viewarticle/540542}}</ref> The PROactive trial had better results using a fibrate with a [[thiazolidinedione]], pioglitazone, but the risk-benefit is not clear in patients with dyslipidemia and diabete. <ref>Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005;366:1279-89.</ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 14:34, 3 November 2009
In medicine, fibrates are antilipemic agents for treating hyperlipidemia. Fibrates lower triglycerides by being agonists of peroxisome proliferator-activated receptor alpha (PPAR alpha)[1] Examples include:
Clinical use
A systematic review of randomized controlled trials of fibrates concluded "In addition to improving lipid profiles, fibrates are associated with an important decrease in nonfatal myocardial infarction, but do not substantially affect all-cause mortality."[2]
Research in synergy
There has been interest in the synergistic use of alpha and gamma PPAR agonists. Trials with dual agonists, the glitazars, were stopped for safety reasons. [3] The PROactive trial had better results using a fibrate with a thiazolidinedione, pioglitazone, but the risk-benefit is not clear in patients with dyslipidemia and diabete. [4]
References
- ↑ Barter PJ, Rye KA (2006). "Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?". Circulation 113 (12): 1553-5. DOI:10.1161/CIRCULATIONAHA.105.620450. PMID 16567579. Research Blogging.
- ↑ Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P et al. (2009). "Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.". Am J Med 122 (10): 962.e1-8. DOI:10.1016/j.amjmed.2009.03.030. PMID 19698935. Research Blogging.
- ↑ Deane Conlon (3 October 2006), "Goodbye Glitazars?", The British Journal of Diabetes and Vascular Disease
- ↑ Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005;366:1279-89.